Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1020214 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.87Day −1.71%Mkt cap $575M1Y +115.8%Off 52W high −17.3%Vol (1Y) 75.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,292 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.8% of sh out |
| Days to cover5.5d |
| 13F net flow (QoQ)+3.36% |
| Top-10 13F concentration61.2% |
| Next report (est.)2026-07-31 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$233.8M |
| Earnings (TTM)-$9.6M |
| ROE−26.0% |
| Net margin−6.7% |
| ROIC−16.8% |
| Sales growth 3Y7.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+39.3% |
| 1Y+115.8% |
| 3Y−6.5% |
| 5Y−43.1% |
| 10Y−61.2% |
| Since incept. (ann.)−2.5% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)75.0% |
| Ann. volatility (3Y)74.4% |
| Sharpe (1Y)1.37 |
| Sharpe (3Y)0.35 |
| Max drawdown (1Y)−38.3% |
| Max drawdown (3Y)−62.2% |
| Beta (3Y vs SPY)2.72 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 21.6M | $39M | 10.77% | −1.6% |
| ARK Investment Management LLC | 19.2M | $35M | 9.56% | +5.3% |
| Soleus Capital Management, L.P. | 10.8M | $20M | 5.37% | +168.8% |
| BAKER BROS. ADVISORS LP | 10.0M | $18M | 4.99% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.1M | $15M | 4.06% | new |
| WASATCH ADVISORS LP | 5.3M | $10M | 2.64% | −3.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 4.6M | $8M | 2.31% | +3.3% |
| Sumitomo Mitsui Trust Group, Inc. | 4.5M | $8M | 2.25% | −4.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-30 | −$0.01 | — | $53.7M | +24.1% |
| 2025-09-30 | 2025-11-06 | $0.00 | — | — | — |
| 2025-06-30 | 2025-08-05 | −$0.03 | — | — | — |
| 2025-03-31 | 2025-05-01 | −$0.04 | — | $43.2M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-31 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Product 88% · Government Contract 12%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
